Journals / Eurasian Journal of Medicine / 2019 / Cilt: 51 - Sayı: 3

Silodosin Has Nocebo Effect on Sexual Adverse Effects: A Randomized Controlled Trial

Pages
277–279
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, be informed about the side effects before treatment is a matter of debate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Nocebo effect is known in patients refered to side effects of drugs that cause more side effects than expected.
📊
Key Findings & Data:Side effects on sexual function have been reported in about 60% of patients using silodosin.
💡
Conclusion & Impact:Therefore, be informed about the side effects before treatment is a matter of debate.
🔬Design:Survey & Empirical Study
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Nocebo effect is known in patients refered to side effects of drugs that cause more side effects than expected. Side effects on sexual function have been reported in about 60% of patients using silodosin. To investigate whether there was nocebo effect of silodosin in the side effects on sexual function.Materials and Methods: Between May 2014 and March 2017, 129 moderate-to-severe LUTS patients were included in the study. For the patients, PSA (ng/mL), prostate volume (cc), uroflowmetry test IIEF-15 and IPSS questionnaires were filled at the time of before and after treatment. Patients were divided into two groups, referred to as side effects that was mentioned and not mentioned. After 3 months control, all patients were asked whether they had sexual side effects. It was analyzed whether there was significantly differences between two groups.Results: The groups were compared in terms of the frequency of androgenic side effects, low semen volume was 40.9% in Group 1 and 22.2% in Group 2 (p=0.04). Anejaculation rates were 6% and 4%, respectively (p=0.12); loss of libido and erectile dysfunction were observed in one patient in both groups (p=0.42). There was no statistically significant difference between the groups for anejaculation, decreased libido and erectile dysfunction. 9 patients (7%) who left medication due to side effects were excluded from the study.Conclusion: In patients, mentioned about the sexual side effects, low semen volume was seen more frequantly, but anejaculation, decreased libido and erectile dysfunction were same. Therefore, be informed about the side effects before treatment is a matter of debate.

🔖

Cite This Article

SERTKAYA, Z., ÖZKAYA, F. (2022). Silodosin Has Nocebo Effect on Sexual Adverse Effects: A Randomized Controlled Trial. Eurasian Journal of Medicine, Cilt: 51 - Sayı: 3, 277–279. https://ajindex.com/articles/508957

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Mondaini N, Gontero P, Giunbilei G, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007; 4: 1708-12 2. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824-37. [CrossRef] 3. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006; 3: 676-81. 4. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61: 917-25. [CrossRef] 5. Capitanio U, Salonia A, Briganti A, Montorsi F. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract 2013; 67: 544-51. [CrossRef] 6. Chapple CR, Montorsi F, Tammela TLJ, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011; 59: 342-52. [CrossRef] 7. Hauser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int 2012; 109: 459-65. 8. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008; 59: 195-206. [CrossRef] 9. Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and metaanalysis. J Sex Med 2014; 11: 1554-66. [CrossRef] 10. El Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. J Sex Med 2006; 3: 144-9. [CrossRef] 11. Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-25. [CrossRef] 12. Walden PD, Durkin MM, Lepor H, Wetzel JM, Gluchowski C, Gustafson EL. Localization of mRNA and receptor binding sites for the A1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 1997; 157: 1032-8. [Cro